Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03895827 · ClinicalTrials.gov registry record · NA
Recovery Initiation and Management After Overdose (RIMO) Experiment
A NA study, sponsored by Chestnut Health Systems.
- Completed
- Registry status
- NA
- Development phase
- 251
- Enrollment target
NCT03895827: Completed NA study, sponsored by Chestnut Health Systems.
NCT03895827 is a NA study that has completed, run by Chestnut Health Systems. The registered enrollment target is 251 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03895827, a NA study, has completed, sponsored by Chestnut Health Systems.
- COMPLETED
- Registry status
- NA
- Development phase
- 251 participants
- Enrollment target
Study Summary
This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Department (CPD); first responders will be trained to seek consent from individuals who are alert and oriented after receiving naloxone for future contacts by research staff as part of the naloxone standard protocol. Those who consent will be contacted and screened for study eligibility ideally within one week of naloxone administration; eligible participants will be randomly assigned either to the control group, i.e., referral to MAT as usual, or to Recovery Initiation and Management after Overdose (RIMO), an assertive linkage and recovery support intervention. This intervention builds on an evidence-based intervention for treatment linkage, monitoring, and recovery support evaluated in 3 prior clinical trials by the study team.
Primary Outcome
Days from index naloxone administration to the initiation of any kind of MAT, from treatment records.
Interventions
- BEHAVIORAL Recovery Initiation and Management after Overdose (RIMO)
- OTHER Passive Referral to Treatment Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2025-06-26 |
| Phase | NA |
What the finished NCT03895827 record still lists
NCT03895827 is an interventional study that assigns participants to a tested intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Recovery Initiation and Management after Overdose (RIMO) is the first listed.
NCT03895827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03895827 about?
NCT03895827 is a clinical study titled "Recovery Initiation and Management After Overdose (RIMO) Experiment". This study targets individuals in Chicago who have received naloxone administered by first responders within the past week to reverse an overdose, but who have not entered into MAT. Study participants will be recruited through partnerships with the Chicago Fire Department (CFD) and/or Police Departm...
What is the current status of trial NCT03895827?
This trial is currently completed. It is a NA study. The enrollment target is 251 participants. The study started on 2022-04-01. Estimated completion is 2025-06-26.
What interventions are being tested in trial NCT03895827?
The interventions under investigation include: Recovery Initiation and Management after Overdose (RIMO) (BEHAVIORAL), Passive Referral to Treatment Control (OTHER).
Who is sponsoring clinical trial NCT03895827?
This trial is sponsored by Chestnut Health Systems, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03895827's enrollment target sits among peer trials
251 410th of 2000 higher than 1,591 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI